Click here for slides on this topic


Linagliptin

An oral antihyperglycemic agent of the dipeptidyl peptidase-4 (DPP-4) inhibitor class.
The following content matched the glossary term: Linagliptin

CompanionSetType2DiabetesMedications

Top

Patient education companion set featuring handouts on DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, and medications used to treat type 2 diabetes (English and Spanish)

Medications Used To Treat Type 2 Diabetes

Top

Patient education handout showing medications used to treat type 2 diabetes and where and how these medications work in the body to lower blood glucose.

Medicamentos para el tratamiento de la diabetes tipo 2

Top

Patient education handout showing medications used to treat type 2 diabetes and where and how these medications work in the body to lower blood glucose—in Spanish.

NDEI.org Expert Commentary on Type 2 Diabetes Treatment Trends from Vivian Fonseca, MD

Top

NDEI Education Council Member Vivian A. Fonseca, MD, comments on a study exploring type 2 diabetes treatment trends in the U.S.: “Clinicians could use these data to determine whether their own prescribing has changed in line with national trends”

Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012

Top

Exclusive! Expert commentary from Vivian A. Fonseca, MD, on this study. Turner LW, Nartey D, Stafford RS, Singh S, Alexander GC. Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012. Diabetes Care. 2014;37:985-992.

ADA 2016 Type 2 Diabetes Pharmacologic Therapy

Top

Pharmacologic treatment options for type 2 diabetes from the 2016 ADA guidelines

Treating the Patient With Type 2 Diabetes and Renal Impairment – References

Top

Patient case: 58-Year-Old African-American Woman with Type 2 Diabetes, Worsening Kidney Function, and Cardiometabolic Comorbidities  

Presented by NDEI Education Council Member, Vivian A. Fonseca, MD

 

Treating the Patient With Type 2 Diabetes and Renal Impairment – Key Take-Home Messages

Top

Patient case: 58-Year-Old African-American Woman with Type 2 Diabetes, Worsening Kidney Function, and Cardiometabolic Comorbidities

Presented by NDEI Education Council Member, Vivian A. Fonseca, MD

 

Treating the Patient With Type 2 Diabetes and Renal Impairment – Follow-Up Pharmacologic Therapy Considerations Proteinuria

Top

Patient case: 58-Year-Old African-American Woman with Type 2 Diabetes, Worsening Kidney Function, and Cardiometabolic Comorbidities  

Presented by NDEI Education Council Member, Vivian A. Fonseca, MD

 

Treating the Patient With Type 2 Diabetes and Renal Impairment – Follow-Up Pharmacologic Therapy Considerations Metformin

Top

Patient case: 58-Year-Old African-American Woman with Type 2 Diabetes, Worsening Kidney Function, and Cardiometabolic Comorbidities  

Presented by NDEI Education Council Member, Vivian A. Fonseca, MD

 

1 2 3 Next 

Slide Library Results

Search Results for: Linagliptin Slides Found: 8
Linagliptin vs Glimepiride for Type 2 Diabetes Not at Goal on Metformin Monotherapy: Design
Linagliptin vs Glimepiride for Type 2 Diabetes Not at Goal on Metformin Monotherapy: Change in A1C from Baseline
Linagliptin vs Glimepiride for Type 2 Diabetes Not at Goal on Metformin Monotherapy: Secondary Endpoints
Linagliptin vs Glimepiride for Type 2 Diabetes Not at Goal on Metformin Monotherapy: CV Safety, Glucose, Adverse Events
DPP-4 Inhibitors: Dosage Adjustment by Degree of Renal Impairment
Incretin Therapies Vs Sulfonylureas Pancreatitis Type 2 Diabetes | NDEI
Empagliflozin Vs Linagliptin First-Line Type 2 Diabetes Treatment ENDO2015 | NDEI
Empagliflozin Vs Linagliptin 2nd-Line Therapy Type 2 Diabetes Obesity ENDO2015 | NDEI